Australia's most trusted
source of pharma news
Posted 3 November 2025 AM
The PBAC has added five new items to its November Agenda, three of them picking up previously deferred considerations.
AbbVie's Elahere will be considered for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer after being deferred in the July meeting. The PBAC said it was of a mind to recommend Elahere, but noted that the MSAC and the TGA are both yet to make their decisions regarding the treatment. The MSAC is considering a test for the presence of folate receptor alpha on tumour cells as an eligibility requirement for Elahere.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.